Among anti-hypertensive therapies, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are considered the cornerstone due to their nephron-protective properties, particularly important in diabetes, and their potential to reduce hepatic inflammation and fibrosis progression, as shown in various clinical studies [86,92]. This evidence concerns the gene ACE and diabetes mellitus.